Might break even with it's old OTC share price, "maybe" except it sells off in to any strength, LOL.
They're living on the 100% dilution Lincoln dilution credit card "line" style financing- and no, it's not anywhere near enough to fund a large, phase II, FDA quality trial.
Lanza in his recent talk was very vague as to when the phase II would even start (as opposed to the 2014 interview where he said "he hoped end of 2014") now he just gave it the ole "we'd hope maybe sometime soon" (paraphrasing).
The "big news" again today barely bumps it and it sells off right into strength like clock work.
The most recent 10-K, PAGE 13:
"Our ability to become profitable depends upon our ability to generate revenue. We do not anticipate generating revenues from product sales for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:"
and PAGE 16:
"Other than our arrangement with Lincoln Park, we have no sources of debt or equity capital committed for funding. Recent attempts to raise capital in the public equity markets have proven unsuccessful, and we can provide no assurance that we will be successful in any future funding effort. "
PAGE 43:
"
We cannot assure you that public or private financing or grants will be available on acceptable terms, if at all. Several factors will affect our ability to raise additional funding, including, but not limited to, the volatility of our common stock and the broader public equity market. If we are unable to raise additional funds, we will be forced to either scale back our business efforts or curtail our business activities entirely. As of December 31, 2014, the Company has an accumulated deficit of $349.1 million, recurring losses from operations, and negative working capital which raise substantial doubt about the ability of the Company to continue as a going concern. Furthermore, an emphasis of matter paragraph related to an uncertainty as to the Company’s ability to continue as a going concern has been included in the auditor’s opinion."
This little news "blip" today- what's it really change in the big picture at this point? They are YEARS away from commercialization in their own words. YEARS. And they need mountains of cash still to even attempt to get there- cash they presently do not have. The big "article" didn't move the needle, the "uplist" didn't move the needle (it's trading below where it did over 3 YEARS ago and is flat at best to its recent OTC levels), all the PR in the world so far has budge it in any meaningful way. I don't see this latest blurb making any big change here- just not seeing it. It sold off already into strength- not a good sign IMO.
